Literature DB >> 32164967

Meloxicam.

Nasr Y Khalil1, Khalid F Aldosari1.   

Abstract

Meloxicam, an oxicam derivative: 4-Hydroxy-2-methyl-N-(5-methyl-2-thiazolyl)-2H-1,2- benzothiazine-3-carboxamide 1,1-dioxide, is a nonsteroidal anti-inflammatory drug (NSAID). It is a selective inhibitor of cyclooxygenase-2 (COX-2). It is used in the management of rheumatoid arthritis, acute exacerbations of osteoarthritis, ankylosing spondylitis and juvenile idiopathic arthritis. It is given in a single oral dose of 7.5mg, increased if necessary to a maximum of 15mg daily (7.5mg in the elderly). It may also be given by rectal suppository in doses similar to those used orally. The reported side effects of meloxicam are similar to those of nonsteroidal anti-inflammatory drugs (NSAIDs), such as abdominal pain, anemia, and edema. There is also an increased risk of serious gastrointestinal (GI) adverse events, including ulceration and bleeding. This profile is prepared to discuss and explain physical characteristics, Proprietary and nonproprietary names of meloxicam. It also includes methods of preparation, thermal and spectral behavior, methods of analysis, pharmacokinetics, metabolism, excretion and pharmacology.
Copyright © 2020 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Analytical methods; Anti-inflammatory; Meloxicam; Pharmacokinetics; Preparation method; Thermal and spectral behavior

Year:  2019        PMID: 32164967     DOI: 10.1016/bs.podrm.2019.10.006

Source DB:  PubMed          Journal:  Profiles Drug Subst Excip Relat Methodol        ISSN: 1871-5125


  6 in total

1.  The Assessment of Meloxicam Phototoxicity in Human Normal Skin Cells: In Vitro Studies on Dermal Fibroblasts and Epidermal Melanocytes.

Authors:  Marta Karkoszka; Jakub Rok; Klaudia Banach; Justyna Kowalska; Zuzanna Rzepka; Dorota Wrześniok
Journal:  Molecules       Date:  2022-06-30       Impact factor: 4.927

2.  Evaluation of analgesic effect, joint function recovery and safety of meloxicam in knee osteoarthritis patients who receive total knee arthroplasty: A randomized, controlled, double-blind study.

Authors:  Feng Hu; Guoya Wu; Quan Zhao; Jian Wu
Journal:  Medicine (Baltimore)       Date:  2021-09-03       Impact factor: 1.817

3.  Developed meloxicam loaded microparticles for colon targeted delivery: Statistical optimization, physicochemical characterization, and in-vivo toxicity study.

Authors:  Syed Abdul Wasay; Syed Umer Jan; Muhammad Akhtar; Sobia Noreen; Rahman Gul
Journal:  PLoS One       Date:  2022-04-25       Impact factor: 3.752

4.  Meloxicam versus Celecoxib for Postoperative Analgesia after Total Knee Arthroplasty: Safety, Efficacy and Cost.

Authors:  Amer Haffar; Yale A Fillingham; Leigham Breckenridge; D'Andrew Gursay; Jess H Lonner
Journal:  J Am Acad Orthop Surg Glob Res Rev       Date:  2022-04-05

Review 5.  Inflammation: A Target for Treatment in Spinal Cord Injury.

Authors:  Ximena Freyermuth-Trujillo; Julia J Segura-Uribe; Hermelinda Salgado-Ceballos; Carlos E Orozco-Barrios; Angélica Coyoy-Salgado
Journal:  Cells       Date:  2022-08-29       Impact factor: 7.666

6.  A New Insight into Meloxicam: Assessment of Antioxidant and Anti-Glycating Activity in In Vitro Studies.

Authors:  Cezary Pawlukianiec; Małgorzata Ewa Gryciuk; Kacper Maksymilian Mil; Małgorzata Żendzian-Piotrowska; Anna Zalewska; Mateusz Maciejczyk
Journal:  Pharmaceuticals (Basel)       Date:  2020-09-10
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.